A Hurry-Up-And-Wait Signal For Clinical Whole Genome Sequencing?

The debate over whether whole-genome sequencing (WGS) can compete with targeted sequencing approaches ratcheted up a notch when WGS service provider Complete Genomics tabled its plan to double capacity until, it said, “demand for clinical-grade genomes supports expansion.” But data interpretation may prove to be as much of a gating factor as sequencing speed or scope.